TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Squamous Non-Small Cell Lung Cancer Therapeutics Market, Global Outlook and Forecast 2023-2035

Squamous Non-Small Cell Lung Cancer Therapeutics Market, Global Outlook and Forecast 2023-2035

  • Category:Life Sciences
  • Published on : 17 August 2023
  • Pages :101
  • Formats:
  • Report Code:SMR-7779383
OfferClick for best price

Best Price: $2600

Squamous NonSmall Cell Lung Cancer Therapeutics Market Size, Share 2023


This report aims to provide a comprehensive presentation of the global market for Squamous Non-Small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Squamous Non-Small Cell Lung Cancer Therapeutics. This report contains market size and forecasts of Squamous Non-Small Cell Lung Cancer Therapeutics in global, including the following market information:

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Revenue, 2018-2023, 20242035, ($ millions)

Global top five companies in 2022 (%)

The global Squamous Non-Small Cell Lung Cancer Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.

BMS-906024 Segment to Reach $ Million by 2029, with a % CAGR in next six years.

The global key manufacturers of Squamous Non-Small Cell Lung Cancer Therapeutics include Ascenta Therapeutics, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bayer AG, BIND Therapeutics, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company and F. Hoffmann-La Roche Ltd., etc. in 2022, the global top five players have a share approximately % in terms of revenue.

We surveyed the Squamous Non-Small Cell Lung Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market, by Type, 2018-2023, 20242035 ($ millions)

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Percentages, by Type, 2022 (%)

BMS-906024

Buparlisib Hydrochloride

FP-1039

Ipilimumab

JNJ-42756493

Lenvatinib

Others

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market, by Application, 2018-2023, 20242035 ($ millions)

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Percentages, by Application, 2022 (%)

Research Center

Hospital

Clinic

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market, By Region and Country, 2018-2023, 20242035 ($ Millions)

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Squamous Non-Small Cell Lung Cancer Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)

Key companies Squamous Non-Small Cell Lung Cancer Therapeutics revenues share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

Ascenta Therapeutics, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

BIND Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Genentech, Inc.

Incyte Corporation

Johnson & Johnson

MacroGenics, Inc.

Novartis AG

Oncogenex Pharmaceuticals, Inc.

PsiOxus Therapeutics Limited

Outline of Major Chapters:

Chapter 1: Introduces the definition of Squamous Non-Small Cell Lung Cancer Therapeutics, market overview.

Chapter 2: Global Squamous Non-Small Cell Lung Cancer Therapeutics market size in revenue.

Chapter 3: Detailed analysis of Squamous Non-Small Cell Lung Cancer Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Squamous Non-Small Cell Lung Cancer Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: The main points and conclusions of the report.

Report Attributes Report Details
Report Title Squamous Non-Small Cell Lung Cancer Therapeutics Market, Global Outlook and Forecast 2023-2035
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2022
Forecast Year 2030
Number of Pages 101 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Introduction to Research & Analysis Reports
1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Overall Market Size
2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size: 2022 VS 2035
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, Prospects & Forecasts: 2018-2035
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Squamous Non-Small Cell Lung Cancer Therapeutics Players in Global Market
3.2 Top Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Squamous Non-Small Cell Lung Cancer Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Squamous Non-Small Cell Lung Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Squamous Non-Small Cell Lung Cancer Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Squamous Non-Small Cell Lung Cancer Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Squamous Non-Small Cell Lung Cancer Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Markets, 2022 & 2035
4.1.2 BMS-906024
4.1.3 Buparlisib Hydrochloride
4.1.4 FP-1039
4.1.5 Ipilimumab
4.1.6 JNJ-42756493
4.1.7 Lenvatinib
4.1.8 Others
4.2 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2024-2035
4.2.3 By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2022 & 2035
5.1.2 Research Center
5.1.3 Hospital
5.1.4 Clinic
5.2 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2024-2035
5.2.3 By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
6 Sights by Region
6.1 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2022 & 2035
6.2 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2024-2035
6.2.3 By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
6.3 North America
6.3.1 By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2018-2035
6.3.2 US Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.3.3 Canada Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.3.4 Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.4 Europe
6.4.1 By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2018-2035
6.4.2 Germany Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.4.3 France Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.4.4 U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.4.5 Italy Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.4.6 Russia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.4.7 Nordic Countries Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.4.8 Benelux Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.5 Asia
6.5.1 By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2018-2035
6.5.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.5.3 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.5.4 South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.5.5 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.5.6 India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.6 South America
6.6.1 By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2018-2035
6.6.2 Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.6.3 Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2018-2035
6.7.2 Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.7.3 Israel Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.7.4 Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
6.7.5 UAE Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, 2018-2035
7 Squamous Non-Small Cell Lung Cancer Therapeutics Companies Profiles
7.1 Ascenta Therapeutics, Inc.
7.1.1 Ascenta Therapeutics, Inc. Company Summary
7.1.2 Ascenta Therapeutics, Inc. Business Overview
7.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.1.4 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.1.5 Ascenta Therapeutics, Inc. Key News & Latest Developments
7.2 AstraZeneca Plc
7.2.1 AstraZeneca Plc Company Summary
7.2.2 AstraZeneca Plc Business Overview
7.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.2.5 AstraZeneca Plc Key News & Latest Developments
7.3 AVEO Pharmaceuticals, Inc.
7.3.1 AVEO Pharmaceuticals, Inc. Company Summary
7.3.2 AVEO Pharmaceuticals, Inc. Business Overview
7.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.3.5 AVEO Pharmaceuticals, Inc. Key News & Latest Developments
7.4 Bayer AG
7.4.1 Bayer AG Company Summary
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Bayer AG Key News & Latest Developments
7.5 BIND Therapeutics, Inc.
7.5.1 BIND Therapeutics, Inc. Company Summary
7.5.2 BIND Therapeutics, Inc. Business Overview
7.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.5.4 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.5.5 BIND Therapeutics, Inc. Key News & Latest Developments
7.6 Boehringer Ingelheim GmbH
7.6.1 Boehringer Ingelheim GmbH Company Summary
7.6.2 Boehringer Ingelheim GmbH Business Overview
7.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.6.5 Boehringer Ingelheim GmbH Key News & Latest Developments
7.7 Bristol-Myers Squibb Company
7.7.1 Bristol-Myers Squibb Company Company Summary
7.7.2 Bristol-Myers Squibb Company Business Overview
7.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.7.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Company Summary
7.8.2 Eli Lilly and Company Business Overview
7.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.8.5 Eli Lilly and Company Key News & Latest Developments
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Company Summary
7.9.2 F. Hoffmann-La Roche Ltd. Business Overview
7.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.9.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.10 Five Prime Therapeutics, Inc.
7.10.1 Five Prime Therapeutics, Inc. Company Summary
7.10.2 Five Prime Therapeutics, Inc. Business Overview
7.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.10.4 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.10.5 Five Prime Therapeutics, Inc. Key News & Latest Developments
7.11 Genentech, Inc.
7.11.1 Genentech, Inc. Company Summary
7.11.2 Genentech, Inc. Business Overview
7.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.11.4 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.11.5 Genentech, Inc. Key News & Latest Developments
7.12 Incyte Corporation
7.12.1 Incyte Corporation Company Summary
7.12.2 Incyte Corporation Business Overview
7.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.12.4 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.12.5 Incyte Corporation Key News & Latest Developments
7.13 Johnson & Johnson
7.13.1 Johnson & Johnson Company Summary
7.13.2 Johnson & Johnson Business Overview
7.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.13.4 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.13.5 Johnson & Johnson Key News & Latest Developments
7.14 MacroGenics, Inc.
7.14.1 MacroGenics, Inc. Company Summary
7.14.2 MacroGenics, Inc. Business Overview
7.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.14.4 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.14.5 MacroGenics, Inc. Key News & Latest Developments
7.15 Novartis AG
7.15.1 Novartis AG Company Summary
7.15.2 Novartis AG Business Overview
7.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.15.4 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.15.5 Novartis AG Key News & Latest Developments
7.16 Oncogenex Pharmaceuticals, Inc.
7.16.1 Oncogenex Pharmaceuticals, Inc. Company Summary
7.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview
7.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.16.4 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.16.5 Oncogenex Pharmaceuticals, Inc. Key News & Latest Developments
7.17 PsiOxus Therapeutics Limited
7.17.1 PsiOxus Therapeutics Limited Company Summary
7.17.2 PsiOxus Therapeutics Limited Business Overview
7.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Major Product Offerings
7.17.4 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global Market (2018-2023)
7.17.5 PsiOxus Therapeutics Limited Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Squamous Non-Small Cell Lung Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers in Global Market
Table 3. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Squamous Non-Small Cell Lung Cancer Therapeutics in Global Market
Table 5. Top Squamous Non-Small Cell Lung Cancer Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Squamous Non-Small Cell Lung Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Squamous Non-Small Cell Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Squamous Non-Small Cell Lung Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2035
Table 12. By Type - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2024-2035
Table 14. By Application ? Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2035
Table 15. By Application - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Global (US$, Mn), 2024-2035
Table 17. By Region ? Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2035
Table 18. By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn), 2024-2035
Table 20. By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2035
Table 22. By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2035
Table 24. By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2035
Table 26. By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2035
Table 28. By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2024-2035
Table 30. Ascenta Therapeutics, Inc. Company Summary
Table 31. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 32. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. Ascenta Therapeutics, Inc. Key News & Latest Developments
Table 34. AstraZeneca Plc Company Summary
Table 35. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 36. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. AstraZeneca Plc Key News & Latest Developments
Table 38. AVEO Pharmaceuticals, Inc. Company Summary
Table 39. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 40. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. AVEO Pharmaceuticals, Inc. Key News & Latest Developments
Table 42. Bayer AG Company Summary
Table 43. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 44. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Bayer AG Key News & Latest Developments
Table 46. BIND Therapeutics, Inc. Company Summary
Table 47. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 48. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. BIND Therapeutics, Inc. Key News & Latest Developments
Table 50. Boehringer Ingelheim GmbH Company Summary
Table 51. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 52. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 53. Boehringer Ingelheim GmbH Key News & Latest Developments
Table 54. Bristol-Myers Squibb Company Company Summary
Table 55. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 56. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 57. Bristol-Myers Squibb Company Key News & Latest Developments
Table 58. Eli Lilly and Company Company Summary
Table 59. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 60. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 61. Eli Lilly and Company Key News & Latest Developments
Table 62. F. Hoffmann-La Roche Ltd. Company Summary
Table 63. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 64. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 65. F. Hoffmann-La Roche Ltd. Key News & Latest Developments
Table 66. Five Prime Therapeutics, Inc. Company Summary
Table 67. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 68. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 69. Five Prime Therapeutics, Inc. Key News & Latest Developments
Table 70. Genentech, Inc. Company Summary
Table 71. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 72. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 73. Genentech, Inc. Key News & Latest Developments
Table 74. Incyte Corporation Company Summary
Table 75. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 76. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 77. Incyte Corporation Key News & Latest Developments
Table 78. Johnson & Johnson Company Summary
Table 79. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 80. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 81. Johnson & Johnson Key News & Latest Developments
Table 82. MacroGenics, Inc. Company Summary
Table 83. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 84. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 85. MacroGenics, Inc. Key News & Latest Developments
Table 86. Novartis AG Company Summary
Table 87. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 88. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 89. Novartis AG Key News & Latest Developments
Table 90. Oncogenex Pharmaceuticals, Inc. Company Summary
Table 91. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 92. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 93. Oncogenex Pharmaceuticals, Inc. Key News & Latest Developments
Table 94. PsiOxus Therapeutics Limited Company Summary
Table 95. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product Offerings
Table 96. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 97. PsiOxus Therapeutics Limited Key News & Latest Developments
List of Figures
Figure 1. Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Type in 2022
Figure 2. Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Application in 2022
Figure 3. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size: 2022 VS 2035 (US$, Mn)
Figure 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, 2018-2035 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2022
Figure 8. By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
Figure 9. By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
Figure 10. By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2035
Figure 11. By Type - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
Figure 12. By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2035
Figure 13. By Application - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
Figure 14. By Region - Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
Figure 15. By Country - North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
Figure 16. US Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 17. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 18. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 19. By Country - Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
Figure 20. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 21. France Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 22. U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 23. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 24. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 25. Nordic Countries Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 26. Benelux Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 27. By Region - Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
Figure 28. China Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 29. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 30. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 31. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 32. India Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 33. By Country - South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
Figure 34. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 35. Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 36. By Country - Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share, 2018-2035
Figure 37. Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 38. Israel Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 39. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 40. UAE Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, (US$, Mn), 2018-2035
Figure 41. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount